X2S fundamentals
An in-depth look to Sinopharm Group Co. Ltd. operating, investing, and financing activities
X2S free cash flow for H1 24 is -5.59 B EUR. For 2023, X2S free cash flow was 1.49 B EUR and operating cash flow was 1.75 B EUR.
0.00
Cash from operating activities
Cash from investing activities
Cash from financing activities
Currency: EUR
TTM